Methylestradiol, sold under the brand names Ginecosid, Ginecoside, Mediol, and Renodiol, is an estrogen medication which is used in the treatment of menopausal symptoms. It is formulated in combination with normethandrone, a progestin and androgen/anabolic steroid medication. Methylestradiol is taken by mouth.

Side effects of methylestradiol include nausea, breast tension, edema, and breakthrough bleeding among others. It is an estrogen, or an agonist of the estrogen receptors, the biological target of estrogens like estradiol.

Methylestradiol is or has been marketed in Brazil, Venezuela, and Indonesia. In addition to its use as a medication, methylestradiol has been studied for use as a radiopharmaceutical for the estrogen receptor.

Methylestradiol is used in combination with the progestin and androgen/anabolic steroid normethandrone (methylestrenolone) in the treatment of menopausal symptoms.

Methylestradiol is marketed in combination with normethandrone in the form of oral tablets containing 0.3 mg methylestradiol and 5 mg normethandrone.

Side effects of methylestradiol include nausea, breast tension, edema, and breakthrough bleeding.

Methylestradiol is an estrogen, or an agonist of the estrogen receptor. It shows somewhat lower affinity for the estrogen receptor than estradiol or ethinylestradiol.

Methylestradiol is an active metabolite of the androgens/anabolic steroids methyltestosterone (17α-methyltestosterone), metandienone (17α-methyl-δ¹-testosterone), and normethandrone (17α-methyl-19-nortestosterone), and is responsible for their estrogenic side effects, such as gynecomastia and fluid retention.